Catalyst Pharmaceuticals, Inc.CPRX

Where CPRX's Net Debt / EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$31.49+0.00 (+0.00%)Previous close
NASDAQHealthcare

CPRX Net Debt / EBITDA: current value, 10-year range and year-by-year history

Net Debt / EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
CPRX Net Debt / EBITDA historyCPRX Net Debt / EBITDA from Dec 2023 to Mar 2026: low -3, high -1.12, latest -2.25.-3.15-2.61-2.06-1.52-0.97Dec 23Jun 24Dec 24Mar 25Sep 25Mar 26med -2.12

CPRX Net Debt / EBITDA by year

Yearly range of CPRX’s net debt / ebitda from 2016 to 2026. Over the full period it ranged from -4.9 to 3.1, averaging -1.5.

CPRX Net Debt / EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
2026-2.3-2.3-2.3-2.3
2025-2.2-2.1-1.9-2.2
2024-3.0-2.4-2.0-2.0
2023-1.1-1.1-1.1-1.1
2022-3.0-2.9-2.8-2.8
2021-3.2-3.0-2.8-3.2
2020-3.1-2.7-2.3-3.1
2019-4.9-1.31.7-2.8
20180.40.61.00.5
20170.41.13.13.1
20160.70.70.70.7

Get notified when CPRX Net Debt / EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

How many years of operating earnings it would take to pay off the company's net debt. The most common leverage ratio — higher means more financial risk and less flexibility.

Formula(Total Debt − Cash) / EBITDA
Full guide
How to read this chart

Watch the trend more than the level. Declining ratio = deleveraging, growing financial flexibility. Rising ratio = increasing leverage, which constrains dividends, buybacks, and future investment.

Key caveats
  • Sector context is essential: 3× is aggressive for a consumer brand but normal for a regulated utility. Always compare to sector peers.
  • Large acquisitions spike the ratio temporarily — check whether the integration plan credibly drives paydown.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.